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Abstract
The tripartite complex AcrAB-TolC is the major efflux system in Escherichia coli. It extrudes a wide spectrum of noxious
compounds out of the bacterium, including many antibiotics. Its active part, the homotrimeric transporter AcrB, is
responsible for the selective binding of substrates and energy transduction. Based on available crystal structures and
biochemical data, the transport of substrates by AcrB has been proposed to take place via a functional rotation, in which
each monomer assumes a particular conformation. However, there is no molecular-level description of the conformational
changes associated with the rotation and their connection to drug extrusion. To obtain insights thereon, we have
performed extensive targeted molecular dynamics simulations mimicking the functional rotation of AcrB containing
doxorubicin, one of the two substrates that were co-crystallized so far. The simulations, including almost half a million
atoms, have been used to test several hypotheses concerning the structure-dynamics-function relationship of this
transporter. Our results indicate that, upon induction of conformational changes, the substrate detaches from the binding
pocket and approaches the gate to the central funnel. Furthermore, we provide strong evidence for the proposed peristaltic
transport involving a zipper-like closure of the binding pocket, responsible for the displacement of the drug. A concerted
opening of the channel between the binding pocket and the gate further favors the displacement of the drug. This
microscopically well-funded information allows one to identify the role of specific amino acids during the transitions and to
shed light on the functioning of AcrB.
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Introduction
The acquisition of multidrug resistance (MDR) by bacteria, both
in hospitals and in the community, has become one of the most
serious impediments to improved healthcare [1–6]. Unfortunately,
MDR is not restricted to antimicrobials, being common to
antimalarials, herbicides, and anticancer agents as well [4]. A key
role in MDR is played by efflux pumps, which feature some
characteristics with respect to common membrane transport
systems [7,8]. Indeed, while the latter typically are highly specific
for their substrates, efflux pumps possess a broad specificity for a
wide range of chemically unrelated molecules and drugs [3–5,9,10].
MDR is of particular concern in Gram-negative bacteria, since
this class includes several human pathogens, e.g., Pseudomonas
aeruginosa and Enterobacter aerogenes [4,5,11,12]. Genetic and bio-
chemical data [12–17] have shown that the major efflux systems in
these bacteria constitute a tripartite complex spanning the
periplasmic space across both the inner and the outer membrane
[18,19]. These efflux systems contain an inner-membrane trans-
porter of the Resistance-Nodulation-Division (RND) superfamily
[6,20,21] and extrude a large variety of toxic compounds, including
novel experimental antimicrobials [22]. In E. coli, the system is
composed of the outer membrane protein TolC [23], the
periplasmic membrane fusion protein AcrA [24,25], and the
inner-membrane cation-drug antiporter AcrB [26,27].
The active part of the efflux pump - AcrB - (see Fig. 1A) is
primarily responsible for the uptake and selectivity of the substrate
as well as for the energy transduction. Its structure has first been
solved as a symmetric homotrimer [27]. Three main domains have
been identified in each monomer: the transmembrane domain
embedded in the inner membrane, which provides the energy
using the transmembrane proton gradient; the pore/pumping
domain in the periplasm, that is supposed to contain the gates
from which substrate uptake and extrusion toward TolC occur
[28,29]; and the TolC docking domain, containing a central
funnel and presumably being in contact with TolC. More recently,
AcrB has been crystallized as an asymmetric trimer with [30] and
without [31,32] a substrate bound in the interior of the protein.
Each monomer was found in a different conformation (hereafter
Loose, Tight, and Open, or L, T, and O, respectively, following
Ref. 31). In the structure of Murakami et al. [30], the drugs
doxorubicin and minocycline were found inside a binding pocket
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in the T monomer. The three conformations of AcrB have been
interpreted as states of a transport cycle, schematically represented
in Fig. 1B, which occurs via a three-step functional (not physical)
rotation [30,31]. Following the hypotheses formulated in Refs. 11,
28, 29, the substrate should enter the pore domain of the
transporter via the L and/or T monomer, either from open clefts
in the periplasm or through grooves between helices at the
interface between pore and transmembrane domain. Then, the
substrate should accomodate into a binding pocket when the
monomer assumes the T conformation and move out toward the
TolC docking domain upon a subsequent change to the
conformation O. The proposed mechanism is primarily based
on the available crystal structures, and has been confirmed only
indirectly [33,34]. Recently, it has been subject of a critical review
[28]. In particular, it is not known how conformational changes of
the protein cause the extrusion of the drug, and to what extent
diffusion is important in the process.
A direct and atomistic-level description of the interplay between
structure and dynamics of the conformational changes might render
the proposed pictures of the function less speculative and allow to
acquire knowledge on the structure-dynamics-function relationship.
Such insights will be of support for the analysis of the huge amount of
genetic, mutagenetic, and other biochemical data on RND
transporters [3–6,9,11,35]. Additionally, they will constitute valuable
information for a structure-based design of efficient antibiotics and
inhibitors, by identifying possible target and key domains in the
different steps of the extrusion process. In this respect, molecular
dynamics (MD) simulations already pinpointed important atomic-
level details of the functioning of TolC [36,37] and MexA [38], a
homologue of AcrA. Despite the importance of AcrB, no
computational studies of this transporter have been reported so far.
Here, we present a first attempt to address the relationship between
functional rotation and extrusion of substrates: starting from the
structural information available on the complex of AcrB with
doxorubicin [30], we simulated the proposed final extrusion step of
the functional rotation. This was done via targeted molecular
dynamics (TMD) simulations [39], which enables to mimic the
conformational changes of the protein without explicitly considering
the proton transfer and the related energy transduction, which would
require the introduction of quantum-mechanical calculations. TMD
has been successfully applied to study conformational changes in large
systems as F1{ATPase [40] and MurD [41], and it has recently
been shown to provide reliable transition paths as compared to other
methods used to sample conformations of proteins [42]. Note that in
this work we are not investigating the issue of substrate specificity of
AcrB, which would require additional compounds to be considered. In
the following we show that doxorubicin leaves the binding pocket
upon induction of functional rotation, although its total extrusion into
the TolC docking domain is not observed. The main aspects as well as
the possible limiting factors of the process are discussed. Furthermore,
we investigate the presence of a peristaltic-like mechanism and
characterize its underlying atomic rearrangements.
Results
The quite modest success in the fight against bacteria endowed
with the MDR machinery [1] is partly due to the lack of
Figure 1. Simulation setup. A) Simulation box: doxorubicin (green)
in the binding pocket of AcrB (L, T, and O monomers are shown in
yellow, blue and red, respectively) embedded in a POPE lipid bilayer
(gray). The system is immersed in a 0.1M KCl solution (ions as spheres,
water as transparent box). A magnification of the binding pocket is
shown in the upright inset. B) Schematic representation of the
functional rotation steps performed here: T?O, i.e., the one proposed
on the basis of the x-ray structures, and T?L.
doi:10.1371/journal.pcbi.1000806.g001
Author Summary
In nature, bacteria have to resist several toxic threats to be
able to survive, from bile acids in intestines up to
antibiotics. The Escherichia coli bacterium, which usually
is a commensal inhabitant of human intestines, can also
acquire pathogenic properties which would harm the
human body. To dispose of toxic compounds, E. coli has
developed a protein machinery which is called ‘‘efflux
pump’’. Here, we studied the dynamics of the transporter
protein AcrB, a component of the E. coli major efflux
system, in complex with an antibiotic (doxorubicin). We
used computer simulations to complement the existing
experimental data. Our purpose was to gain more detailed
insights into the pumping mechanism at the molecular
level. In our simulations the drug leaves the binding
pocket upon induction of functional rotation in the
protein, although a complete extrusion was never
observed. A peristaltic motion, which starts with a
zipper-like closure of the interior of the protein, is an
important step for the extrusion of the drug. Interestingly,
such a peristaltic mechanism of pumping has been
suggested before on the basis of structural data. The
molecular details obtained in this study shall deepen the
understanding of the functioning of the efflux pump.
Drug Extrusion via Functional Rotation in AcrB
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knowledge of the connections between structural and dynamical
features, which determine the function of the efflux systems at the
molecular level. In an effort to shed some light thereon, we
investigated to what extent drug motion is related to the suggested
extrusion step of the functional rotation. To this end, we started
from the T state for the occupied monomer, wherein the
anthracycline antibiotic doxorubicin was co-crystallized previously
[30]. Then, the transition T?O, i.e., the final extrusion step of the
functional rotation proposed in Refs. 30–32, is enforced via TMD.
Note that such a short notation highlights the conformational
changes of the T monomer, but all other monomers are also
forced toward their corresponding conformations, i.e., T?O is
equivalent to L{T{O?T{O{L (see Fig. 1B). The main
results presented below stem from simulations in which all heavy
atoms of the protein were steered. To estimate possible side effects
of the TMD approach, we further discuss the results from TMD
simulations where only Ca atoms were steered (see Tab. S1 for a
list of all the performed TMD simulations). During all the TMD
simulations, doxorubicin is not steered by the external bias that
drives the conformational changes of the protein, but it is free to
move. In the T conformation, the suggested entrance from the
periplasm to the binding pocket is opened and the exit gate toward
the central funnel is closed (see Fig. 1B). In the O conformation,
the closing/opening configuration is toggled, hence the substrate
should be able to move out of AcrB toward TolC [32].
Displacement of the Drug
Initially, doxorubicin is found within a binding pocket which is
located between b{sheets of the subdomains PC1 and PN2 [30]
and formed by the residues F136, Q176, F610, F615, F617, and
F628 [35], as shown in the inset of Fig. 1A. During the transition,
these subdomains undergo conformational changes, thereby
displacing the drug. In general, the whole binding region, which
contains the described binding pocket has a quite large internal
volume, probably with more than one binding site [4].
Fig. 2 displays the calculated distance between the centers of
mass (CoMs) of the binding pocket and doxorubicin, dDOX{BP, as
a function of the simulation time, along with the values of the
interaction energy. At the end of the TMD simulations, the
RMSD of the protein with respect to the target (T{O{L) is
*0:6 A˚ (Fig. S1), indicating that the transition has been
accomplished. Furthermore, the substrate has moved away from
the binding pocket by a total distance of*8 A˚ toward the gate to
the central funnel, formed by the residues Q124, Q125, and Y758
[32]. As shown in the inset of Fig. 2, the interaction energy
increases significantly as the transition proceeds, thereby denoting
an unbinding event.
The initial and final positions of the drug of one of the TMD
simulations are shown in Fig. 3, as well as the structural changes of
the binding pocket and of the gate to the central funnel. The
displacement of doxorubicin toward the gate is confirmed by the
profile of the distance between the CoMs of the three residues
forming the gate and that of doxorubicin (data not shown). During
the T?O transition, this distance decreases by *7 A˚, which is a
clear indication of the movement of the drug along the path that
was identified by Sennhauser et al. [32]. Note that the magnitude
of displacement is essentially independent of the initial orientation
of doxorubicin within the binding pocket (see Fig. S2). Addition-
ally, the obtained displacements are almost insensitive to randomly
reinitializing the initial velocities of all atoms or to extending the
simulation time to 5 and 10 ns (Fig. S3). In these longer
simulations, the major movement of doxorubicin occurs at a
different relative time, with respect to the total TMD simulation
time, although the final displacements are very similar to those
seen in the shorter runs. This indicates a minor dependence of our
general results on the simulation time and fortifies the reliability of
our calculations.
To assess the stability of doxorubicin in the final position at the
end of the TMD runs, we performed two sets of four standard MD
simulations starting from the final TMD configurations (see Figs. 2
and S4). In the first case, we restrained the Ca atoms of the
protein, in order to keep the backbone in the final T{O{L
conformation. In the second one, we left the system completely
unrestrained and free to relax. In half of the unrestrained
simulations, the drug moves further away from the binding pocket
by 2 A˚ in the direction of the gate; in all the remaining runs (2
unrestrained and 4 restrained), it oscillates around its final TMD
position. Nevertheless, doxorubicin does not move back toward
the binding pocket in any of these simulations.
From the visual inspection of the final position of doxorubicin as
shown in Figs. 3A and B, it is clear that the drug did not enter the
central funnel of the TolC docking domain during the T?O
transition. Certainly, the real time scale of the process is out of
reach by the computational tools used in the present work, and
such a limitation might be a reason for the absence of the complete
extrusion in our simulations. Indeed, diffusion could play a
relevant role in driving out the drug from AcrB, but this process
would occur on a time scale hardly approachable by our protocol.
Apart from methodological issues, additional factors have been
suggested to be necessary for the full extrusion of the substrate. For
example, the necessity of cooperativity effects associated with the
binding of a second substrate (absent in our simulations) to a
neighboring monomer has been invoked to interpret kinetic data
[43]. Furthermore, a more involved pattern of configurations
assumed by the monomers and connected to the extrusion process
has also been inferred from the analysis of crystallographic
structures [28,44]. A further possible reason might be the absence
of the membrane fusion protein AcrA. Its contribution to the
functionality of the efflux system seems to go beyond a simple
structural linker between TolC and AcrB. Surely, a deeper
understanding of this interplay will benefit from the simulations of
the entire system exploiting the model recently proposed by
Symmons et al. [25].
Figure 2. Movement of doxorubicin within the protein. Plot of
the distance between the CoMs of doxorubicin and the binding pocket,
dDOX{BP (solid curve), as a function of the simulation time during the
T?O transition. The curve represents an average over simulations with
k~3 kcal mol{1A
0{2 and different initial velocities (see Methods). Also
shown are the same distances during ensuing standard MD simulations
with restraints on Ca atoms of the protein (dot-dashed), and without
restraints (dashed). The interaction energy is given in the inset.
doi:10.1371/journal.pcbi.1000806.g002
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Note that upon induction of the conformational transition
T?O, the subdomain PC2 moves inward to close the entrance
and is followed by PN1 which opens the exit [31] (Fig. 3B). The
distance between the CoMs of PN2 and PC1 declines (see Fig. S5)
accompanied by a rotation of the two subdomains, thereby
resulting in a shrinkage of the binding pocket. Thus, the motions of
the subdomains appear to be the first requirement for the
squeezing of the drug out of the binding pocket. However, the
largest displacements between the CoMs of the subdomains do
occur in the first half of the TMD simulation, while most of the
drug displacement is seen in the second half (see Figs. 2, S5, and
Video S1). Interestingly, the RMSD of the residues of the binding
pocket from the target does not drop much until almost half of the
TMD simulation is over. Then, it starts to decrease in correlation
with the movement of the drug (Fig. S1), indicating that more
specific and local conformational changes are involved in the
unbinding of doxorubicin. Thus, our attention focused on the
action of specific groups of residues.
Evidence for Peristaltic Motion
A peristaltic pumping was proposed as the extrusion mechanism by
Pos and coworkers in 2006 [31]. To identify possible fingerprints of
the peristaltic action and correlations between motions of residues
and drug displacement, we compared the latter with the evolution of
the minimum distances, dmin, between selected couples of residues in
the binding pocket. In particular, we selected those pairs of residues
whose distances decline predominantly during the T?O transition,
namely F136–F615, F136–F617, F136–F628, and Q176–F615. In
Fig. 4, the evolution of their average minimum distances over 5 TMD
simulations (lower panel) is shown together with three representative
configurations associated therewith (upper panel). Interestingly, the
changes in the distances among the selected residues occur in a step-
wise fashion, with residue pairs at the ‘‘bottom’’ of the binding pocket
closing first, and those at the ‘‘top’’ last, producing a zipper-like
motion.
The first reduction of dmin affects the pair F136–F628, but the
substrate essentially keeps its position in the binding pocket.
Successively, the residues F136 and F617 approach each other,
and dDOX{BP starts to increase (I in lower panel of Fig. 4). The
configurations assumed by the three residues are displayed in
snapshot I of the upper panel in the same figure. At about one
third of the TMD simulation time, the distance of F136–F615
starts to decrease, and this reduction correlates with a large
movement of the drug (II in Fig. 4). Note that this is the largest
reduction (*5 A˚) in the distance among the observed pairs of
residues. At approximately the same time, the squeezing motion
between Q176 and F615 takes place, which is also related to a
substantial displacement of the drug (III in Fig. 4). These two
amino acids happen to act as a clamp for the planar rings of
doxorubicin. The phenyl ring of F615 is atop of one of the rings
belonging to the drug and the Q176 amide is on the other side.
While the drug is moving toward the gate, the connection between
the ring of F615 and the drug is changing from one planar ring of
the drug to the next one in a stepwise fashion. Once the residues
F615 and Q176 squeeze the substrate out of the binding pocket
and thereby close the return path of doxorubicin (see snapshot III
in the upper panel of Fig. 4), the drug is able to move further away
from the binding pocket.
Figure 3. Drug displacement and conformational changes of the protein along the transition T?O. A) Movement of the drug from the
binding pocket toward the gate (yellow and red represent the initial and final configuration, respectively). It can be seen from the comparison of the
two conformations that residues F136 and F628 in the bottom of the binding pocket and F615 and Q176 in the upper part, are mostly involved in the
squeezing of the binding pocket; interestingly residue F610, which mutagenesis experiments have shown to be important for the activity of the
pump, seems not directly involved in pumping the substrate out of the binding pocket; B) Porcupine plot of the conformational changes of the
subdomains in the pore domain (arrows represent the displacement, in A˚, from the initial position of the Ca atoms of each amino acid, colored
according to the color scale bar). Important subdomains are highlighted: PN2 (transparent blue), PN1 (transparent green), and PC2 (transparent red).
As PC1 lacks major changes, it is omitted for clarity. The movement of the drug toward the central funnel is also shown (color code as in panel A); C)
Opening of the gate (residues Q124, Q125, and Y758, yellow space-filling representation) and of the BP-Gate path (backbone representation, formed
by residues 48–50, 85–89, 126, 163, 177–181, 273–276, and 767–772 of the occupied monomer T - gray - as well as residues 67–70 and 113–117 of the
neighboring monomer O - orange, see also text). Transparent and solid representations refer to initial and final states of the T?O step, respectively.
This allows to better appreciate the opening of a path towards the TolC docking domain. For the sake of clarity when compared to the other panels,
the final conformations of doxorubicin (transparent stick representation) and the binding pocket (black-and-white sticks) are also shown.
doi:10.1371/journal.pcbi.1000806.g003
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Concerning each individual TMD simulation, the connection
between the zipper-like closure of the binding pocket and the drug
displacement can be seen in 4 out of 5 different 1-ns-long
simulations (Figs. S6A, C, D, and E). A three-step mechanism can
be roughly recognized in the graphs, with a sequential closure of
the pairs from the innermost (F136–F628) to the outermost one
(Q176–F615). The remaining run of this set (Fig. S6B) could be
viewed as a borderline case in which the last step is very short.
Despite this, the closure of the binding pocket maintains a basically
sequential character, where the outermost pairs (Q176–F615 and
F136–F615) close after the innermost ones (F136–F617 and F136–
F628). Additionally, three longer TMD simulations (two of 5 ns
and one of 10 ns) were performed to assess the dependence of our
results from the simulation time (Figs. S6F, G, and H,
respectively).
As expected, the molecular details of the process (final
displacement, side chain conformation and dynamics) are slightly
sensitive to the simulation protocol (see also Fig. S3). Nevertheless,
a sequential closure of the binding pocket is still detectable in all
panels of Fig S6. In addition to the four out of the five 1-ns-long
simulations mentioned above, in one out of the two 5-ns-long ones
evidences of a three-step mechanism are recognizable (see caption
of Fig. S6 for an extended discussion). Unfortunately, a meaningful
statistics, needed for a thorough discussion of the possible limits
inherently present in the TMD protocol, is out of range for these
longer trajectories.
It is worthwhile to point out that the results of recent
mutagenesis experiments [35] have evidenced a significant impact
of the mutation F610A on the minimum inhibitory concentration
of doxorubicin, while other mutations, including those of the
phenylalanines 136, 178, 615, 617, and 628 to alanine, showed
smaller effects. According to our simulations, F610 is not
prominently involved in the zipper-like action, but might act as
binding partner when doxorubicin enters the pore domain, and/or
might close the escape from the binding pocket toward the
periplasm. Upon mutation to alanine, these actions might not be
efficient anymore. Additional studies are required to gain insight
into the effect of the F610A mutation.
Further Essentials of Drug Displacement
To enhance the understanding of the results presented above,
we investigated the dynamical coupling between squeezing
motions of the binding pocket and other specific residues located
beyond it. In particular, we chose those residues lining the path
from the binding pocket toward the exit gate. This path (hereafter
called BP-Gate path and sketched in Fig. 3C) is formed, with
reference to the initial conformation, by the residues 48–50, 85–
89, 126, 163, 177–181, 273–276, and 767–772 of the occupied
monomer T as well as residues 67–70 and 113–117 of the
neighboring monomer O. A series of TMD simulations have been
performed in which we kept the BP-Gate path of the T monomer
unsteered and forced only the rest of the protein, thereby applying
the same bias as in the previous TMD simulations. According to
our results, doxorubicin leaves the binding pocket also in these
simulations, but the overall displacement is smaller by*3 A˚ with
respect to the one shown in Fig. 2. Indeed, the BP-Gate path
remains too narrow for doxorubicin to leave the binding region
and to move toward the exit gate. Furthermore, the drug is tilted
by*900 with respect to the final position in Fig. 3A (see Fig. S7),
which also hinders further motion toward the gate. This result
emphasizes the importance of a concerted opening of the BP-Gate
path in addition to the zipper-like closure of the binding pocket.
Since the position and the orientation of amino acids seem to be
important for the displacement of the drug from the binding
pocket, we further extended our set of simulations to shed more
light on this aspect. In the dynamics described so far, all non-
hydrogen atoms have been targeted, which corresponds to a
forced movement of the side chains during the TMD simulation.
To analyze the importance of these movements for the drug
displacement in comparison to the influence of the backbone/
subdomain, we performed a series of TMD simulations where only
the Ca atoms were targeted. This also allowed to test the influence
of the biasing force on our results, as a large fraction of the protein
is now free to move. We observed a significant displacement of the
drug during this set of TMD simulations (see Fig. S8), in
qualitative agreement with those obtained by targeting all heavy
atoms, hinting at the importance of subdomain motions for the
displacement of the substrate (see Fig. 5). On average, the
displacement is reduced by *3:5 A˚ with respect to the one
reported in Fig. 2. Clearly, the number of possible paths explored
by the drug is expected to increase when targeting only the Ca,
due to the larger flexibility of the protein. Consistently, a
displacement comparable to that shown in Fig. 2 is observed only
in 3 out of 10 TMD simulations (data not shown). In addition, in
some of the 7 remaining runs, doxorubicin does not move straight
toward the exit gate, but also turns slightly aside where the interior
along the BP-Gate path leaves space to roam. These results
indicate that the arrangement of the side chains is able to
significantly influence the maximal displacement of the drug.
Additionally, we performed a simulation with a lower force
constant (see Tab. S1). The aim was to obtain an indication of the
minimal force required to accomplish the conformational changes
in the protein, especially along the BP-Gate path. It turns out that,
Figure 4. Sequence of the peristaltic squeezing. Upper panel:
Snapshots extracted from the MD simulations represent configurations
just after the squeezing of certain residue pairs in comparison to the
initial state (snapshot labeled ‘‘Zero’’ on the left, solid stick represen-
tation). For each snapshot only those residues which are mainly
involved in the squeezing step are highlighted. Lower panel: Minimum
distances between selected pairs of residues of the binding pocket,
dmin , as a function of the simulation time. To better identify different
behaviors, we reported running averages (step length equal to 10) of
the raw data. The tiny-dotted line represents the distance between the
CoMs of the binding pocket and doxorubicin (as plotted in Fig. 2).
doi:10.1371/journal.pcbi.1000806.g004
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during the entire TMD simulation, the distance of doxorubicin
from the binding pocket is lower by a couple of A˚ with respect to
that in previous simulations with larger force constants (Fig. S9).
This is related to a larger RMSD of the binding pocket from the
target along the simulation (inset in Fig. S9), which, although very
small, has an important effect on the displacement of the drug. In
combination with the results of the TMD simulations where only
Ca atoms have been targeted, these findings highlight the
importance of individual residues including their side-chain
conformations for the displacement and subsequent extrusion of
doxorubicin.
Reversing the Direction of the Cycle
Analyzing the asymmetric crystal structures of AcrB [30–32], it
is reasonable to suppose that drugs exit the transporter from the
monomer in the O conformation. Therefore, we have considered
the direct transition T?O at first. However, the possibility of a
functional transition from T to O via the L conformation cannot
be ruled out a priori. Thus, we carried out simulations for the two
steps of the reverse cycle direction, i.e., T?L and L?O (Fig. 6).
The investigation is important for two reasons. Firstly, the
direction T?O has been suggested to be the functional one from
analyses of structural data [30–32], but it lacks a direct proof.
Secondly, the comparison between the two directions should give a
better picture of the conformational changes and drug-amino-acid
interactions which are mainly involved in the displacement of the
drug.
Interestingly, the specific movements of PN2 and PC1, which
have been described above as responsible for the shrinkage of the
binding pocket during T?O, can also be observed during T?L
(data not shown). Indeed, the substrate tends to leave the binding
pocket in both cycle directions. However, in contrast to T?O, the
drug displacement never exceeds *2 A˚ for T?L, hence
doxorubicin does not approach the exit gate. This can be
attributed to the quite large internal volume of the binding region
[4]. Therefore, substrates may exploit their flexibility and change
their orientation. Importantly, the drug does not move remarkably
during the second step L?O of the reverse cycle as well. Again,
this points to the need of a concerted closure of the binding pocket
and widening of the channel toward the exit gate.
Discussion
The molecular dynamics underlying the functioning of many
active transporters, which include efflux transporters of the RND
family, are not fully understood yet. Although the increasing
number of crystal structures permits us to have a closer look at the
atomic details of the structure, the dynamical aspects are not
caught, and only hypotheses can be advanced concerning the
functional mechanisms. MD simulations with atomistic detail are
an appropriate tool to investigate structure-function-dynamics
relationship in these systems. In this work, we performed TMD
simulations to investigate the relations between supposed func-
tional motions in AcrB [30–32] and the extrusion of the antibiotic
doxorubicin without explicitly considering the energy supply
associated with the proton gradient across the inner membrane.
Figure 5. The peristaltic motion of the subdomains. Porcupine plot
(as in Fig. 3) of the backbone motion of the subdomains PC1 and PN2
including the Ca atoms of the residues used in Fig. 4 (initial and final
position of these atoms and doxorubicin in yellow and red, respectively).
doi:10.1371/journal.pcbi.1000806.g005
Figure 6. Comparing the two possible directions of the functional cycle. A) Plot of dDOX{BP as a function of the TMD simulation time during
T?O (red curve) and T?L (green curve). The violet curve represents dDOX{BP during the step L?O that is the subsequent transition in the reverse
cycle (see main text for more details). The values of the force constant for both simulations is k~3 kcal mol{1A
0{2 . B) Representation of the initial
(yellow) and final [color code as in panel A] configurations of the drug.
doi:10.1371/journal.pcbi.1000806.g006
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Our results show a detachment of the drug from its initial
binding pocket within the T monomer. Moreover, during the
T?O step of the functional rotation, doxorubicin travels by*8 A˚
and approaches the gate to the central funnel. Importantly, this
movement is believed to be part of the suggested extrusion process
in AcrB. Our data also support the proposed peristaltic pumping
mechanism, and highlight the atomistic dynamics at its basis. In
particular, there is evidence to suggest a zipper-like squeezing of
the binding pocket, which leads to an unbinding of the substrate
along the T?O direction of the cycle. The closing of the binding
pocket is initially caused by the movements of adjacent
subdomains, whereas the rearrangements of individual residues
lining the binding pocket strongly influence the detachment of
doxorubicin in the end. The molecular details of the extrusion
process depend slightly on the TMD simulation protocol
(simulation length, targeted atoms), but the main features are
robust against these changes.
While investigating the feasibility of the cycle in the reverse
direction T?L?O, additional simulations have shown a similar
squeezing of the binding pocket during the T?L transition.
However, no substantial movement of the drug toward the gate
has been seen. This could mainly be due to the lack of concerted
widening of the BP-Gate path and the exit gate. Moreover, even if
such movements do occur during the subsequent L?O step, they
are not coupled to squeezing of the binding pocket, and do not
cause any significant movement of the substrate. Altogether, these
results strongly points at L?T?O as the legit direction of the
functional rotation.
Although a substantial movement of the substrate was seen in our
TMD simulations of the T?O transition, the drug never reached the
central funnel of the TolC docking domain, which is a necessary step
to achieve the full extrusion of the drug out of AcrB. One possibility to
explain this is that further movement of the drug might just be
directed diffusion within a confined geometry occurring on a time
scale much larger than that captured in the simulations. In addition,
the motion of the drug might further be enhanced by attractive
interactions between the substrate and residues around the gate or
even TolC, or by the presence of other substrates. Finally, the
influence of the neighboring monomers as well as the other proteins
constituting the efflux pump have to be understood. In the long run, it
would be very important to model the whole tripartite efflux pump,
i.e., AcrB together with TolC and AcrA. This could complete the
picture of the protein-protein interactions involved and their
cooperative effects on the drug extrusion. Nonetheless, using the
present results it should be possible to obtain a better understanding
of the structure-function relationship in RND transporters and its
connection to dynamical aspects. Finally, molecular insights on the
efflux mechanism in AcrB might be of help for the research on
human RND transporter, e.g., the Niemann-Pick C1 disease protein
and the hedgehog receptor Patched [28].
Methods
System Setup
For our simulation setup, the crystal structure from Ref. 32 was
chosen. After addition of hydrogen atoms, a restrained structural
optimization was performed. The structure of doxorubicin was
taken from Ref. 30 and placed into the system in the same relative
position within the binding pocket as original. The latter structure
was not used since several loop residues (499 to 512) of the pore
domain were not resolved, and the resolution was lower with
respect to that in Ref. 32. The combination of a crystal structure
with a substrate from another structure was possible since the
binding pocket of the protein accommodates the drug very well;
indeed, doxorubicin keeps its position during the equilibration.
Moreover, the RMSD between the Ca of the structures from Refs.
30, 32 is less than 1 A˚. After the placement of the drug, a second
relaxation was performed. The protein-substrate complex was
inserted into a pre-equilibrated POPE lipid bilayer, which is
parallel to the x-y plane, and solvated in TIP3P water with a
physiological KCl concentration of 0.1 M. At the end of the
buildup phase, all lipid and water atoms which overlapped with
the protein were artificially removed; the total number of atoms of
the system is 451,962. This setup leads to a periodic box size of
*172|169|184 A
03.
Force Fields Parameters
The AMBER force field parm99 [45] was used for the protein,
the TIP3P parameters for water [46], and Aaqvist’s parameters for
the ions [47]. For doxorubicin several parameters were taken from
the GAFF force field [48] while the missing ones were generated
using modules of the AMBER package [49]. In particular, atomic
restrained electrostatic potential (RESP) charges were derived
using antechamber, after a structural optimization performed with
Gaussian03 [50]. The GAFF parameters for the POPE lipids were
generated following the protocol in Ref. [51].
Simulation Protocol
The unbiased and the targeted MD simulations were both
performed with the program NAMD 2.7b1 [52]. After an initial
energy minimization, the system was gradually heated up to
600 K and finally quenched to 310 K. All these simulations were
performed in the presence of restraints on the phospholipids and
the heavy atoms of the the protein. A time step of 1 fs was used for
the integration of equations of motion. Furthermore, periodic
boundary conditions were employed, and electrostatic interactions
were treated using the particle-mesh Ewald (PME) method, with a
real space cutoff of 12 A˚ and a grid spacing of 1 A˚ per grid point
in each dimension. The van der Waals energies were calculated
using a smooth cutoff (switching radius 10 A˚, cutoff radius 12 A˚).
Furthermore, the simulations were performed in the NpT
ensemble and the temperature was kept at 310 K by applying
Langevin forces to all heavy atoms with the Langevin damping
constant set to 5 ps{1. The pressure was kept at 1.013 bar using
the Nose´-Hoover Langevin piston pressure control.
The functional rotation was simulated by means of TMD [39]
(built-in module of NAMD) which allows to induce conformation
changes between two known states. To prevent any hindrance on
the T monomer by the neighboring ones, we also steered those
toward their next state. Note that the TMD algorithm has recently
been demonstrated to produce reliable transition paths as
compared to other methods [42]. In this respect, to assess the
influence of the biasing force on the dynamics of the system, we
performed a series of TMD simulations using different values for
the force constant per atom (k~2,3,and 4 kcal mol{1A
0{2) and
the simulation time (1, 5, and 10 ns). The results discussed in the
main paper refer to simulations of 1 ns with k~3 kcal mol{1A
0{2,
which are consistent with the literature [40,41,53]. All TMD
simulations performed are detailed in Tab. S1 together with the
comparison among distances between CoMs of doxorubicin and
the binding pocket and the final positions of the drug (Fig. S2).
The setup, the analyses as well as the atomic-level figures, were
performed using VMD [54].
Supporting Information
Figure S1 Drug displacement vs. protein conformational
change. Plot of the distance between the CoMs of doxorubicin
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and that of the binding pocket, dDOX-BP, (red full line) and of the
RMSD of the whole protein with respect to the target structure
(black dashed line), as a function of the TMD simulation time
during the TRO transition. The time evolution of the RMSD of
the binding pocket from the target structure is also shown (blue
dot-dashed line).
Found at: doi:10.1371/journal.pcbi.1000806.s001 (0.68 MB TIF)
Figure S2 Profiles of dDOX-BP for two different conformation
and orientation of the drug along the TRO transition. A) Profiles
of dDOX-BP for the TMD simulation discussed in the main text (red
full line) and for one simulation in which doxorubicin is in a
different conformation and orientation within the binding pocket
(green dashed line). In the inset is reported the behavior of the
interaction energy between the drug and the residues of the
binding pocket. Also shown are the two different initial positions -
B) top view; D) side view - as well as (D) the final positions of the
drug.
Found at: doi:10.1371/journal.pcbi.1000806.s002 (0.40 MB TIF)
Figure S3 Drug displacement vs. simulation parameters along
the TRO transition. A) Distance dDOX-BP as a function of the
percentage of TMD simulation time for the set of simulations
where all heavy atoms have been targeted. To better identify
different behaviours, we report running averages of lenght 10 of
the raw data. Varying the initial velocities within the set of
simulations of same lenght and k value does not remarkably alter
the profile of dDOX-BP. Extending the simulation time does not
sensitively affect the final position of the drug, although the profile
of dDOX-BP show some differences with respect to the former set; B)
Final positions of doxorubicin in the same set of simulations. The
CoMs of the drug are shown as filled spheres to highlight the
similar displacements of the drug despite the difference which can
be seen in the orientation.
Found at: doi:10.1371/journal.pcbi.1000806.s003 (0.35 MB TIF)
Figure S4 Profile of dDOX-BP after the TRO step. The panel
reports the behavior of dDOX-BP in eight post-TMD simulations.
Two sets of such simulations (each 2 ns long) have been performed
starting from the final configurations found in each of the TMD
simulations with k = 3 and TMD time 1 ns. In the first set we have
removed all the restraints from the system, in the second we have
restrained Ca atoms. It can be seen that in half of the simulations
without restraints the drug moves further towards the gate, while
in the remaining ones it oscillates around the final position.
Importantly, doxorubicin never goes back towards the binding
pocket.
Found at: doi:10.1371/journal.pcbi.1000806.s004 (0.07 MB TIF)
Figure S5 Drug displacement vs. subdomains movements in the
periplasmic region. A) Time evolution of dsub, the distance
between CoMs of the subdomains (shown in panel B) of AcrB
mostly involved in the conformational changes during the TRO
transition (see also Video S1). Larger changes in the PC1-PC2 (red
line), PN2-PC2 (yellow line) and PC1-PN2 (magenta line) distances
occur within the first half of the simulation, while the displacement
of the substrate, dDOX-BP (black dotted line, arbitrary units),
essentially increases in the second half. B) Top view of the
aforementioned subdomains (doxorubicin is shown as red-sticks).
Found at: doi:10.1371/journal.pcbi.1000806.s005 (0.45 MB TIF)
Figure S6 ‘‘Peristaltic’’ closing of the binding pocket induces
squeezing of the drug. Profile of the minimum distance dmin
between selected pairs of residues within the binding pocket, as a
function of the TMD simulation time during the TRO transition.
Results are shown from eight simulations in which all heavy atoms
are steered. In each panel we reported the corresponding profile of
dDOX-BP (red dotted lines, rescaled to fit in the graph). To better
identify different behaviors, we report running averages of lenght
10 of the raw data. In 4 out of 5 the 1 ns long TMD simulations
(panels A, C, D, E) a three-steps zipper-like closure of the residues
lining the binding pocket can be roughly appreciated. Panel B
shows a slightly different behavior, which could be viewed as a
limit process in which the last step is very short. It is worthwhile to
point out that also in this case the closure of the binding pocket
occurs in a sequential manner, with outermost pairs F176–F615
and F136–F615 closing after the innermost ones. In panel F (5 ns
long TMD) two steps can be roughly identified; again, the
innermost pair F136–F628 closes before the others and the
outermost 176–615 as last. The second 5 ns long simulation, panel
G, shows a clearer three-steps behavior. The 10 ns simulation
(panel H) also shows a zipper-like closure of residues in the binding
pocket, although this appear less evident than in the previous
cases. Indeed, distances between the innemost pairs, F136–F628
and F136–F617, reduce from ,7.5 to ,4 A˚ in about 3 ns, while
during this time interval the outermost pairs F136–F615 and
F176–F615 close only partially, going the corresponding minimum
distances from ,9 to ,7 A˚ and from ,7 to ,5 A˚ respectively.
Careful inspection of the graphs reveals that a further step,
occurring about 1 ns later, is necessary for their complete closure.
Additionally, it can be seen that the distances between outermost
pairs drops at almost equivalent time. Concerning the 5 ns and
10 ns simulations, we would like to stress that, due to the large
computational time needed to perform them, obtaining a relevant
statistics is out of reach.
Found at: doi:10.1371/journal.pcbi.1000806.s006 (0.14 MB TIF)
Figure S7 Effect of targeting the BP-Gate path on the
movement of the drug. A) View of the BP-Gate path. Amino
acids in monomers T and O are shown in blue and red,
respectively (in silver the binding pocket, in transparent yellow the
gate); B) Final configurations obtained respectively from TMD
simulations performed with (doxorubicin colored in red) and
without (cyan) bias applied to the BP-Gate path for the (TRO
transition; the initial position of the drug is shown in transparent
yellow). The differences in the structure of the BP-Gate path
between the ‘‘standard’’ TMD simulation and the one without the
bias on the BP-Gate path are represented using a color scale tuned
on the value of the RMSD with respect to the final structure from
‘‘standard’’ TMD run; C) Evolution of dDOX-BP (main graph) and
of the RMSD (inset) as a function of TMD simulation time for the
two simulations (color code as in B).
Found at: doi:10.1371/journal.pcbi.1000806.s007 (0.69 MB TIF)
Figure S8 Effect of targeting side chains on the displacement of
doxorubicin. Plot of dDOX-BP as a function of the simulation time
during the TRO transition for two sets of TMD simulations
(averages are shown): Steering all heavy atoms (red line); Steering
only Ca (green line).
Found at: doi:10.1371/journal.pcbi.1000806.s008 (0.01 MB TIF)
Figure S9 Drug displacement vs. value of the force constant
used for TMD. A) Plot of dDOX-BP (main graph) and of the RMSD
of the binding pocket (inset) as a function of the TMD simulation
time during the TRO transition for two values of the force
constant applied on all heavy atoms, k = 3 kcal mol21 A˚22 (red
full curve represents an average from all the runs having different
initial velocities), k = 2 kcal mol21 A˚22 (magenta dashed curve). B)
Representation of the initial (yellow) and final (color code as in
panel A) configurations of the drug. Note how small differences in
the structure of the binding pocket affect the value of the drug
displacement.
Found at: doi:10.1371/journal.pcbi.1000806.s009 (0.02 MB TIF)
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Table S1 Details of the different simulations. Shown are the
cycle direction, the simulation time, the force constant, the selected
atoms for the TMD, the number of simulations with the same
setup, and the length of post-equilibration standard MD
simulations after the targeting was finished, with or without
restraints on the Ca atoms.
Found at: doi:10.1371/journal.pcbi.1000806.s010 (0.08 MB RTF)
Video S1 Movement of doxorubicin and of the four subdomains
PC1, PC2, PN1, PN2 extracted from one TMD simulation along
the TRO transition. Firstly the whole trimer is shown, then zoom
is performed on the T monomer, in the region around the drug.
Doxorubicin is shown initially in blue, and becomes red following
the TMD time. Some residues of the binding pocket are also
highlighted.
Found at: doi:10.1371/journal.pcbi.1000806.s011 (8.52 MB MP4)
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